Loading
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Latest quote
$0.417
−$0.0332 · -7.37%
After-hours
$0.4002
−$0.0168 · -4.03%
Oct 8, 5:22 PM ET
Regular session · ET · Market data may be delayed.
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Day range
Current $0.417
52-week range
Current $0.417
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
58
Fair Value
Sentiment
41
Mixed
Risk
84
Extreme Risk
Momentum
29
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Day range
Current $0.417
52-week range
Current $0.417
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 41K USD | — | 2.23M USD | 3.03M USD | 2.31M USD |
| Gross profit | −41K USD | — | −2.23M USD | −3.03M USD | −2.31M USD |
| Research and development | 1.52M USD | 8.42M USD | 39.18M USD | 63.95M USD | 53.54M USD |
| Selling, general, and administrative | 3.95M USD | 4.14M USD | 9.32M USD | 12.21M USD | 11.02M USD |
| Operating expenses | 2.39M USD | 16.25M USD | 48.5M USD | 73.13M USD | 64.42M USD |
| Interest income | 511K USD | 184K USD | 850K USD | 689K USD | 368K USD |
| Interest expense | — | −5K USD | 1.31M USD | 3.36M USD | 15K USD |
| Depreciation and amortization | 41K USD | 823K USD | 2.23M USD | 3.03M USD | 2.31M USD |
| Operating income | −2.43M USD | −16.25M USD | −50.73M USD | −76.16M USD | −66.72M USD |
| Net income | −1.92M USD | −15.75M USD | −51.6M USD | −77.53M USD | −66.37M USD |
Company facts updated Oct 8, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jan 16, 2025 | 1:50 | — | — |
Stock split | Apr 4, 2023 | 1:15 | — | — |
Effective Jan 16, 2025
1:50
Effective Apr 4, 2023
1:15
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
